120477-27-2

Upstream product

• 120476-96-2 (3S,4S)-4-<(tert-butyloxycarbonyl)amino>-5-cyclohexyl-2-(diethoxymethyl)-3-hydroxy-1-pentene 
• 98105-42-1 (S)-2-(t-butoxycarbonylamino)-3-cyclohexyl-1-propanal 
• 120476-98-4 (4S,5S)-4-(cyclohexylmethyl)-5-(3',3'-diethoxy-2'-propenyl)oxazolidin-2-one 

Downstream Products

• 120477-04-5 (4S,5S,2'S)-5-<1'-<(tert-butyldimethylsilyl)oxy>-3'-(methylsulfonoxy)-2'-propyl>-4-(cyclohexylmethyl)oxazolidin-2-one 
• 120477-05-6 (4S,5S,2'R)-5-<1'-<(tert-butyldimethylsilyl)oxy>-3'-(methylsulfonoxy)-2'-propyl>-4-(cyclohexylmethyl)oxazolidin-2-one 
• 120477-08-9 (4S,5S,2'R)-5-<3'-azido-1'-<(tert-butyldimethylsilyl)oxy>-2'-propyl>-4-(cyclohexylmethyl)oxazolidin-2-one 
• 120477-09-0 (4S,5S,2'S)-5-<3'-azido-1'-<(tert-butyldimethylsilyl)oxy>-2'-propyl>-4-(cyclohexylmethyl)oxazolidin-2-one 
• 120477-06-7 (4S,5S,2'R)-5-(3'-azido-1'-hydroxy-2'-propyl)-4-(cyclohexylmethyl)oxazolidin-2-one 
• 120477-07-8 (4S,5S,2'S)-5-(3'-azido-1'-hydroxy-2'-propyl)-4-(cyclohexylmethyl)oxazolidin-2-one 
• 120477-02-3 (4S,5S,2'R)-5-<1'-<(tert-butyldimethylsilyl)oxy>-3'-hydroxy-2'-propyl>-4-(cyclohexylmethyl)oxazolidin-2-one 
• 120477-03-4 (4S,5S,2'S)-5-<1'-<(tert-butyldimethylsilyl)oxy>-3'-hydroxy-2'-propyl>-4-(cyclohexylmethyl)oxazolidin-2-one 
• 120574-39-2 (2S,3S,4S)-4-amino-1-azido-5-cyclohexyl-3-hydroxy-2-(hydroxymethyl)pentane 
• 120477-18-1 (4S,5S)-4-(cyclohexylmethyl)-5-<3'-(mesyloxy)-2'-propenyl>oxazolidin-2-one 
• 120477-01-2 (4S,5S)-5-<3'-<(tert-butyldimethylsilyl)oxy>-2'-propenyl>-4-(cyclohexylmethyl)oxazolidin-2-one 
• 120477-19-2 (4S,5S)-4-(cyclohexylmethyl)-5-<3'-azido-2'-propenyl>oxazolidin-2-one 

Relevant academic research and scientific papers

Azido Glycols: Potent, Low Molecular Weight Renin Inhibitors Containing an Unusual Post Scissile Site Residue

Azidomethyl-substituted 1,2- and 1,3-diols were prepared from Boc-cyclohexylalanal and evaluated as transition state analogue renin inhibitors, leading to the development of a small (MW 600), nanomolar inhibitor.Remarkable aqueous solubility enhancement followed the incorporation of an N-terminal urea functionality.Evaluation of selected compounds both in vivo and in vitro demonstrated that while transport across the intestine occurred upon id administration, extensive liver extraction resulted in low systemic levels.